Analysts Confirm Bullish Outlook on Wave Life (WVE) Over Obesity Treatment
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the 13 hot stocks to buy with the highest upside potential. On February 5, BofA initiated coverage of Wave Life Sciences Ltd.
Wave Life Sciences Ltd. (WVE)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | RA Capital Management Peter Kolchinsky | 18,203,009 | $309,451,153 | +1% | 3.17% |
| 2. | Adage Capital Management Phill Gross And Robert Atchinson | 9,786,061 | $166,363,037 | -33% | 0.25% |
| 3. | Maverick Capital Lee Ainslie | 9,280,237 | $157,764,029 | +11% | 1.69% |
| 4. | Darwin Global Management Abhishek Trehan | 7,298,421 | $125,167,920 | 2.53% | |
| 5. | Driehaus Capital Richard Driehaus | 6,581,067 | $111,878,139 | +5% | 0.76% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $19.00 | 1,470,000 | $27,930,000.00 | 18,245,691 | 2025-12-11 | Filing | |
| $6.69 | 1,000 | $6,687.50 | 18,203,009 | 2025-11-13 | Filing | |
| $8.00 | 2,791,930 | $22,335,440.00 | 16,775,691 | 2024-09-27 | Filing | |
| $5.00 | 3,300,000 | $16,500,000.00 | 13,983,761 | 2023-12-07 | Filing | |
| $5.00 | 1,000,000 | $5,000,000.00 | 18,202,009 | 2023-12-11 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $13.45 | 3,588 | $48,258.60 | 134,385 | 2026-02-09 | Filing | |
| $13.45 | 10,480 | $140,956.00 | 275,520 | 2026-02-09 | Filing | |
| $13.45 | 1,883 | $25,326.35 | 61,867 | 2026-02-09 | Filing | |
| $13.45 | 3,228 | $43,416.60 | 408,246 | 2026-02-09 | Filing | |
| $16.70 | 1,295 | $21,626.50 | 25,000 | 2026-01-02 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 18,245,691 | $310,176,747 | 38.82% | |
| 2. | 15,135,983 | $257,311,705 | 0.01% | |
| 3. | 12,648,907 | $215,031,419 | 0% | |
| 4. | 4,744,520 | $80,656,840 | 0.13% | |
| 5. | 4,095,282 | $69,619,794 | 0.05% |
News See All
13 Hot Stocks to Buy with the Highest Upside Potential
On average, equities are expected continue to deliver positive results in 2026, this time with greater breadth across sectors, styles, and regions, compared to the other periods of the recent bull market...
BofA Highlights WVE-007 as Primary Driver For Wave Life Sciences Ltd. (WVE)'s Growth, Projecting Peak Sales Above $11B
TheFly reported on February 5 that Bank of America (BofA) initiated coverage of WVE with a Buy rating and a price target of $38.
Wave Life Sciences (WVE) to Benefit From Optimism Surrounding Alpha-1 Antitrypsin Deficiency Program
As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish. The stock received coverage from 15 analysts, all of whom assigned Buy ratings.
15 Innovative Healthcare Stocks to Buy According to Analysts
Over the last two years, artificial intelligence has propelled global financial markets into a boom, with stocks reaching all-time highs.
17 Biotechnology Stocks with More Than 50% Upside
2025 was a year characterized by both challenges and opportunities for the biotechnology sector.
Wave Life Sciences (WVE) Regains Rights to Potential Rare Genetic Disorder Treatment
On February 2, Wave Life Sciences Ltd. (NASDAQ:WVE) said it regained full rights to WVE-006, a potential treatment for alpha-1 antitrypsin deficiency, a rare genetic disorder, from GSK.
13 Best Revenue Growth Stocks to Buy Right Now
Speaking to CNBC on January 13, Ari Wald, Head of Technical Analysis at Oppenheimer, said U.S.
Wave Life Sciences (WVE) Emerges as Obesity Treatment Contender, Oppenheimer Boosts Price Target
Wave Life Sciences Ltd. (NASDAQ:WVE) ranks among the best stocks under $25 to buy now. On December 16, Oppenheimer boosted its price target for Wave Life Sciences Ltd.
Wave Life Sciences’ (WVE) RNA Obesity Drug WVE-007 Shows Potential to Match GLP-1 Efficacy Without Muscle Loss
Wave Life Sciences Ltd. (NASDAQ:WVE) is one of the low priced stocks to buy with high upside potential.
Hedge Fund Resource Center Billionaire Hedge Funds
